WHO suggestions require manufacturers to put into practice a constant risk administration system for sterility test isolators, like regular possibility assessments and the development of chance-primarily based Management methods. Manufacturers wanting to employ these strategies must present robust validation facts to show their equivalence to pharmacopoeial solutions. Continue to Successfully Submitted (Awaiting Approval)